Phase 1 Head and Neck Cancer Trial, Recruiting NCT07567235 Sponsor: West China Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 1 Head and Neck Cancer Trial, Recruiting

NCT07567235
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old at the time of screening, of any gender
  • People who have been diagnosed with head and neck squamous cell carcinoma (a specific type of cancer affecting the head and neck area, but not the nasopharynx) confirmed through a tissue sample, and who are scheduled to receive radiation therapy after surgery
  • People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (called the ECOG scale, scores 0–2)
  • People whose blood counts, liver function, kidney function, and heart function all meet certain minimum levels, as measured by blood tests taken within 7 days before starting treatment (confirm with trial site for exact values required)
  • People who are able to understand the study information and are willing to sign a consent form before any study procedures begin

Who may not be able to join:

  • People who have open wounds, skin inflammation, skin breakdown, or other skin problems in the area where the treatment would be applied, or who have tattoos or other permanent skin markings in that area that could make it hard to observe skin reactions
  • People who have certain conditions affecting connective tissue or the skin throughout the body, such as lupus, dermatomyositis, scleroderma, or similar conditions
  • People who have a known allergy to the study drug or any of its ingredients, or who have had a severe allergic reaction to any drug, food, or vaccine in the past
  • People who have any serious uncontrolled illness — such as heart, lung, kidney, nerve, blood, digestive, or hormonal conditions — or a psychiatric condition such as depression or schizophrenia, that the study doctor believes could interfere with the trial
  • People who have taken part in another clinical trial of a drug or medical device within the 3 months before screening
  • People with a history of drug or alcohol misuse or addiction
  • People who are pregnant or breastfeeding, or people (or their partners) who are planning to become pregnant at any point from screening until 12 months after the last dose of the study treatment
  • People whom the study doctor considers unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8618980606753

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
West China Hospital
Registry
ClinicalTrials.gov
Start date
15 June 2026
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Dose-Limiting Toxicities (DLTs); Incidence and Severity of Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov